Literature DB >> 17506479

Improved method to calculate the antibody avidity index.

C T Perciani1, P S Peixoto, W O Dias, F S Kubrusly, M M Tanizaki.   

Abstract

The methods currently used to determine the immunoglobulin avidity index (AI) require the choice of a reference point in the ELISA titration curve. Since both curves, with and without denaturating reagents, seldom run in parallel, the AI value becomes highly dependent on this reference. The new method for AI calculation presented here takes into account the whole data of the ELISA titration curve in which the final numerical AI is the average of each point. (c) 2007 Wiley-Liss, Inc.

Mesh：

Substances：

Year:  2007        PMID： 17506479      PMCID： PMC6649193          DOI： 10.1002/jcla.20172

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN： 0887-8013            Impact factor:   2.352


  20 in total

1.  A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.

Authors:  M H Korhonen; J Brunstein; H Haario; A Katnikov; R Rescaldani; K Hedman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Vaccines for prevention of meningococcal disease.

Authors:  A J Pollard; M Levin
Journal:  Pediatr Infect Dis J       Date:  2000-04       Impact factor: 2.129

3.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

Authors:  J W Tappero; R Lagos; A M Ballesteros; B Plikaytis; D Williams; J Dykes; L L Gheesling; G M Carlone; E A Høiby; J Holst; H Nøkleby; E Rosenqvist; G Sierra; C Campa; F Sotolongo; J Vega; J Garcia; P Herrera; J T Poolman; B A Perkins
Journal:  JAMA       Date:  1999-04-28       Impact factor: 56.272

4.  A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.

Authors:  Manmohan Singh; Mildred Ugozzoli; Jina Kazzaz; James Chesko; Elawati Soenawan; Donatella Mannucci; Francesca Titta; Mario Contorni; Gianfranco Volpini; Giuseppe Del Guidice; Derek T O'Hagan
Journal:  Vaccine       Date:  2005-10-06       Impact factor: 3.641

5.  Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Authors:  Clementien L Vermont; Harry H van Dijken; Ronald de Groot; Germie P J M van den Dobbelsteen
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

6.  Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity.

Authors:  P A Jenum; B Stray-Pedersen; A G Gundersen
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

7.  Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

Authors:  D Goldblatt; A R Vaz; E Miller
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

8.  Humoral immune response to primary rubella virus infection.

Authors:  Kim M Wilson; Carlie Di Camillo; Larissa Doughty; Elizabeth M Dax
Journal:  Clin Vaccine Immunol       Date:  2006-03

9.  Comparison of two commercially available avidity tests for toxoplasma-specific IgG antibodies.

Authors:  Cosme Alvarado-Esquivel; Shneh Sethi; Klaus Janitschke; Helmut Hahn; Oliver Liesenfeld
Journal:  Arch Med Res       Date:  2002 Nov-Dec       Impact factor: 2.235

10.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease.

Authors:  J Boslego; J Garcia; C Cruz; W Zollinger; B Brandt; S Ruiz; M Martinez; J Arthur; P Underwood; W Silva
Journal:  Vaccine       Date:  1995-06       Impact factor: 3.641
View more
  19 in total

1.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

2.  A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2017-05-05       Impact factor: 3.641

3.  Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance.

Authors:  Martina Kosikova; Lei Li; Peter Radvak; Zhiping Ye; Xiu-Feng Wan; Hang Xie
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

4.  Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies.

Authors:  Lenka Fialová; Milada Petráčková; Oliver Kuchař
Journal:  J Clin Lab Anal       Date:  2017-01-26       Impact factor: 2.352

5.  A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.

Authors:  Stephen A Kaba; Clara Brando; Qin Guo; Christian Mittelholzer; Senthilkumar Raman; David Tropel; Ueli Aebi; Peter Burkhard; David E Lanar
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

6.  Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease.

Authors:  K A Gelderman; A C A D Drop; L A Trouw; H J Bontkes; G Bouma; I M W van Hoogstraten; B M E von Blomberg
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.

Authors:  Rama Jayaraj; David Piedrafita; Terry Spithill; Peter Smooker
Journal:  Genet Vaccines Ther       Date:  2012-08-31

8.  Assessment of the quality and quantity of naturally induced antibody responses to EBA175RIII-V in Ghanaian children living in two communities with varying malaria transmission patterns.

Authors:  Hamza B Abagna; Festus K Acquah; Ruth Okonu; Nii A Aryee; Michael Theisen; Linda E Amoah
Journal:  Malar J       Date:  2018-01-08       Impact factor: 2.979

9.  Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery.

Authors:  David Peterhoff; Stefanie Thalhauser; Jan M Sobczak; Mona O Mohsen; Christoph Voigt; Nicole Seifert; Patrick Neckermann; Alexandra Hauser; Song Ding; Quentin Sattentau; Martin F Bachmann; Miriam Breunig; Ralf Wagner
Journal:  Vaccines (Basel)       Date:  2021-06-11

10.  A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Elena A Kashentseva; John Paul Villegas; Alejandra Fernandez; Amelia Van Pelt; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.